PHARMANUTRA S.P.A. Logo
IT0005274094
A2DU6N
PHN.MI

PHARMANUTRA S.P.A.

Loading quotes...

Forecast

There is no analyst data available for this company.

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, PHARMANUTRA S.P.A. has already paid €1.20 in dividends. The last payout was in May.

Financials

In the last quarter, PHARMANUTRA S.P.A. had revenue of €40.5M and net profit of €6.47M
(EUR) June 2026
YoY
Revenue 40.5M 11.66%
Gross profit 26.7M 8.64%
Net profit 6.47M 4.12%
EBITDA 11.1M 3.70%

Fundamentals

Metric Value
Market capitalization
€712.39M
Number of shares
9.58M
52-week high/low
€95.90 - €44.60
Dividend yield
1.61%
Dividends TTM
€1.20
Beta
0.18
P/E ratio
34.13
PEG ratio
1.47
P/B ratio
10.23
P/S ratio
4.99

Company profile

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

Name
PHARMANUTRA S.P.A.
CEO
Andrea Lacorte
Headquarters Pisa, pi
Italy
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
07/18/2017
Employees 144

Ticker symbols

Exchange Symbol
Mil
PHN.MI
Frankfurt
761.F
Düsseldorf
761.DU
Milan
PHN.MI
München
761.MU
🍪

Parqet  uses cookies. Learn more